The frequency of SREs in EGFR mutated lung cancer with bone metastases have been scarcely documented in literature (Table 4) and the benefit of TKIs on bone pain and SREs prevention have not evaluated in randomized clinical trials (11). Here, EGFR is linked to lung carcinoma.